No Detail Found!

Present trends in the treatment of advanced non-small-cell lung Cancer.

Author(s)
Tariq Parvez Department of Oncology, King Fahad Hospital, Al-Madina Al-Munawar, KSA
Ayman Iskandrani Department of Oncology, King Fahad Hospital, Al-Madina Al-Munawar, KSA
Abdullah Rida Allam Department of Thoracic Surgery, King Fahad Hospital, Al Medina Al Munawara, KSA
Muhammad Ali Khan Department of Chest Medicine, King Fahad Hospital, Al Medina Al Munawara, KSA
Abstract
Lung cancer is the leading cause of cancer deaths all over the world. As most patients present with advanced disease, major efforts have been made in the treatment of such disease with systemic chemotherapy. Several new agents and new combinations of chemotherapy have been developed recently. This article reviews the randomized clinical trials investigating chemotherapy for advanced non-small cell ling cancer (NSCLC) in relapse or progressive disease while being treated and in elderly patients. Therapies that incorporate new biological agents to target specific defects in lung cancer are also discussed. Several clinical trials has demonstrated improvement in overall survival as well as quality of life with presently available chemotherapy treatment of advanced NSCLS. Better options are available for the elderly as well as those having relapse after first-line  chemotherapy. Despite all this progress the 5-years survival rate still remains at a dismal 14%. New therapies with good results are still desired.
Publication Details
Page(s) 483-490
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 13, Issue: 8, Year: 2003

Request the full text from PASTIC

0

Citations

0

Downloads

71

Views